AUS
NZ
UK
CA
USA
IND
SELLAS Life Sciences Group, Inc. revealed that a sole arbitrator dismissed its claims in a binding arbitration against 3D Medicines, Inc., overseen by the Hong Kong International Arbitration Centre. SELLAS has been mandated to pay roughly $1.0 million towards 3D Medicines' legal fees and expenses. Despite this ruling, 3D Medicines confirmed it will proceed with the development and commercialization of galinpepimut-S (GPS) in Greater China, with substantial milestone payment opportunities still intact under their exclusive license agreement.
Key Points
- NASDAQ: SLS
- On July 24, 2026, a sole arbitrator dismissed SELLAS's claims against 3D Medicines in arbitration administered by the Hong Kong International Arbitration Centre
- SELLAS ordered to pay approximately $1.0 million toward 3D Medicines' legal fees; $191.5 million in potential future milestone payments remain under the exclusive license agreement as of March 31, 2026
- SELLAS reported unaudited cash and cash equivalents of $138.3 million as of June 30, 2026
Arbitrator Rejects SELLAS Claims in Dispute with 3D Medicines
On July 24, 2026, a sole arbitrator ruled in the binding arbitration between SELLAS Life Sciences Group, Inc. and 3D Medicines, Inc., administered by the Hong Kong International Arbitration Centre, dismissing all of SELLAS's claims. This ruling resolves a dispute initiated by SELLAS concerning their collaboration on galinpepimut-S, a therapeutic candidate targeting the Greater China market.
The arbitration, governed by HKIAC rules, allowed the arbitrator to allocate dispute-related costs. Consequently, SELLAS must cover approximately $1.0 million of 3D Medicines' legal fees and expenses, reflecting the financial impact of the unsuccessful arbitration.
Milestone Payment Dispute and License Agreement Details
The arbitration centered on milestone payments related to galinpepimut-S’s development and commercialization in Greater China. Specifically, $13.0 million in milestone payments were contested during the arbitration. These payments are part of a broader $191.5 million potential milestone pool under the exclusive license agreement as of March 31, 2026.
Following the arbitrator's decision, 3D Medicines affirmed its commitment to continue advancing galinpepimut-S per the license agreement, indicating the partnership remains intact despite the dispute.
SELLAS’s Financial Position as of Mid-2026
SELLAS reported an unaudited cash and cash equivalents balance of approximately $138.3 million as of June 30, 2026. This preliminary figure is subject to finalization upon completion of financial closing and management review processes and may differ from the audited results.
This cash reserve supports ongoing operations and R&D efforts. However, the arbitration-related $1.0 million payment will reduce this amount once finalized.
Galinpepimut-S Development and Market Strategy in Greater China
Galinpepimut-S (GPS) is the focal therapeutic asset in the SELLAS and 3D Medicines collaboration. The exclusive license grants 3D Medicines rights to develop and commercialize GPS in Greater China, a key market for oncology and immunotherapy. The continuation of GPS development by 3D Medicines post-arbitration highlights the asset’s commercial potential in the region.
The arbitration dispute did not jeopardize the partnership but involved contractual interpretations related to milestone payments. The $191.5 million in remaining milestone payments as of March 31, 2026, represents SELLAS’s potential upside if GPS meets development and commercialization targets.
International Arbitration and Regulatory Framework
The Hong Kong International Arbitration Centre was chosen for its neutral, international forum suitable for cross-border commercial disputes, reflecting the global nature of the SELLAS-3D Medicines partnership. Under HKIAC rules, the arbitrator exercised discretion to allocate legal fees, resulting in SELLAS bearing approximately $1.0 million of 3D Medicines’ defense costs.
The arbitration decision is binding and enforceable under international conventions, limiting SELLAS's options to challenge the ruling except on narrow legal grounds.
Financial and Strategic Implications of Arbitration Outcome
The arbitration ruling imposes a $1.0 million legal fee obligation on SELLAS, directly impacting its cash reserves. Additionally, the contested $13.0 million milestone payments are no longer recoverable, removing a potential near-term revenue source.
Despite this, SELLAS’s cash position of $138.3 million as of June 30, 2026, remains strong relative to the arbitration costs, supporting ongoing business activities. The ruling may affect investor perceptions of SELLAS’s contractual relationships and dispute management.
Outlook for SELLAS and Asset Monetization
The arbitration loss highlights challenges SELLAS faces in monetizing out-licensed assets and managing partnerships. Galinpepimut-S remains a key asset, with 3D Medicines holding development and commercialization rights in Greater China. The $191.5 million in potential milestone payments offers continued value if development milestones are met.
SELLAS’s ability to track GPS progress and validate milestones will be crucial for realizing these payments. Investors will likely monitor updates on GPS development and milestone achievements closely.
Disclosure and Regulatory Status
SELLAS confirmed it is not designated as an emerging growth company under the Securities Act of 1933 or the Securities Exchange Act of 1934, subjecting it to full compliance with applicable accounting and disclosure standards. This is reflected in the detailed arbitration and financial disclosures.
The company’s headquarters are at 7 Times Square, Suite 2503, New York, NY 10036, with securities traded on Nasdaq under ticker symbol SLS. Incorporated in Delaware with SEC file number 001-33958, SELLAS operates as a publicly traded biopharmaceutical entity under SEC oversight.
